Tilray Brands Launches New High-CBD Product for UK Market
Tilray Brands has announced the UK launch of a new high-CBD, low-THC medical cannabis flower product targeting anxiety and stress-related conditions. The product, cultivated under EU-GMP standards, will be available through Tilray's existing UK clinic partnerships and reflects growing demand for balanced cannabinoid profiles among patients sensitive to psychoactive effects.
Tilray Brands has confirmed the UK launch of a new medical cannabis flower product with a high-CBD, low-THC cannabinoid profile, targeted at patients managing anxiety, stress-related conditions and mild to moderate chronic pain where psychoactive effects are undesirable.
The product, which carries EU-GMP certification and is cultivated under controlled indoor conditions in Portugal, will initially be available through Tilray's existing network of UK clinic and pharmacy partners. The company expects full national distribution within three months of launch.
Who Is This Product For?
Many patients — particularly those new to medical cannabis or those with sensitivity to THC — have expressed a preference for high-CBD preparations that deliver therapeutic effects without significant psychoactivity. The new Tilray product joins a growing category of CBD-dominant options in the UK licensed market, offering prescribers greater flexibility when tailoring treatment plans.
Tilray's clinical advisory team noted that the product is particularly suited to daytime use, where maintaining cognitive function and workplace productivity is important for patients managing long-term conditions.
UK Market Strategy
The launch reflects Tilray's broader strategy of expanding its UK portfolio beyond high-THC flower products, which have historically dominated the licensed cannabis market. By offering a broader cannabinoid spectrum, the company aims to address a wider patient population and reduce the proportion of patients seeking unlicensed products through alternative channels. Pricing will be in line with comparable UK market products, the company confirmed.
